yttrium radioisotopes has been researched along with Ovarian Neoplasms in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (14.71) | 18.7374 |
| 1990's | 10 (29.41) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 2 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Massuger, LF; Moreno, M; Oei, AL; Sweep, FC; Thomas, CM; Verheijen, RH; von Mensdorff-Pouilly, S | 1 |
| Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK | 1 |
| Alvarez, R; Grizzle, W; LoBuglio, A; Meredith, R; Partridge, E; You, Z | 1 |
| Alvarez, RD; Austin, JM; Barnes, MN; Carey, D; Grizzle, WE; Huh, WK; Khazaeli, MB; Kilgore, LC; LoBuglio, AF; Meredith, RF; Partridge, EE; Schlom, J; Shen, S | 1 |
| Boerman, OC; Boonstra, H; Corstens, FH; Dijkgraaf, I; Edwards, DS; Frielink, C; Janssen, ML; Massuger, LF; Oyen, WJ; Rajopadhye, M | 1 |
| Enmon, RM; Finn, RL; Kolbert, KS; Koutcher, JA; Larson, SM; Matei, C; Palm, S; Sgouros, G; Xu, S; Zanzonico, PB | 1 |
| Blumenthal, RD; Goldenberg, DM; Leone, E; Modrak, D; Rodriguez, M | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Colombo, N; Grana, C; Handkiewicz, D; Malavasi, F; Mangioni, C; Paganelli, G; Rocca, P | 1 |
| Adams, GP; Brechbiel, MW; Dadachova, E; Horak, EM; Klein-Szanto, AJ; Marks, JD; Shaller, CC; Simmons, HH; Tesfaye, A; Weiner, LM | 1 |
| Boerman, O; Corstens, F; Dijkgraaf, I; Edwards, DS; Frielink, C; Janssen, M; Liu, S; Massuger, L; Oyen, W; Rajopadhye, M | 1 |
| Bombardieri, E; Bongarzone, I; Canevari, S; Coliva, A; Figini, M; Giussani, A; Luison, E; Martin, F; Seregni, E; Tomassetti, A; Zacchetti, A | 1 |
| Albone, EF; Berger, MA; Grimm, LG; Masters, GR; Scully, MS; Singleton, J; Soltis, DA | 1 |
| Albone, EF; Berger, MA; Masters, GR | 1 |
| Sabbatini, P; Spriggs, DR | 1 |
| Benigno, BB; Epenetos, AA; Falke, T; Jobling, T; Lambert, J; Lopes, A; Markowska, J; Massuger, LF; Seiden, MV; Soper, JT; Spiegel, G; Stamp, G; Thurston, D; Verheijen, RH; Vyzula, R | 1 |
| Benigno, BB; Epenetos, AA; Lopes, A; Massuger, LF; Oei, AL; Seiden, MV; Soper, JT; Verheijen, RH | 1 |
| Massuger, LF; Oei, AL; Oyen, WJ | 1 |
| Amano, R; Kawai, K; Mori, H; Ogawa, K; Shikano, N; Washiyama, K; Yoshimoto, M | 1 |
| Adelstein, SJ; Atcher, RW; Bloomer, WD; Lambrecht, RM; Madara, JL; McLaughlin, WH; Milius, RA; Mirzadeh, S; Wolf, AP; Zalutsky, MR | 1 |
| Kairemo, KJ; Ljunggren, K; Stigbrand, T; Strand, SE; Wahlström, T | 1 |
| Epenetos, AA; Gooden, CS; Kosmas, C; Maraveyas, A; Snook, D | 1 |
| Hiltunen, J; Kairemo, K; Laine, A; Ljunggren, K; Nikula, T; Penttilä, P; Strand, SE; Wahlström, T | 1 |
| Epenetos, AA; Hird, V; Kosmas, C; Lambert, HE; Maraveyas, A; Meares, CF; Snook, D | 1 |
| Dhokia, B; Epenetos, AA; Hird, V; Lambert, HE; Maraveyas, A; Mason, P; Meares, C; Snook, D; Soutter, WP; Stewart, JS | 1 |
| Borchardt, PE; Freedman, RS; Quadri, SM; Vriesendorp, HM | 2 |
| Malygina, AI; Nikitina, RG | 1 |
| Burke, TW; Cheung, L; Cunningham, JE; Kavanagh, JJ; Lamki, L; Rosenblum, MG; Shanken, LJ; Silva, EG; Thompson, L; Wharton, JT | 1 |
| Courtenay-Luck, NS; Epenetos, AA; Gooden, CS; Kosmas, C; McCall, MJ; Meares, CF; Snook, D | 1 |
| Dhokia, B; Hird, V; Hooker, G; Lambert, HE; Papadimitriou, JT; Rowlinson, G; Sivolapenko, G; Snook, D; Stewart, JS; Sullivan, M | 1 |
| Coulter, C; Dhokia, B; Epenetos, AA; Hird, V; Lambert, HE; Mason, WP; Snook, D; Soutter, WP; Stewart, JS | 1 |
| Epenetos, AA; Hird, V; Snook, D; Stewart, JS; Sullivan, M | 1 |
| Epenetos, AA; Hird, V; Myers, MJ; Snook, D; Stewart, JS; Sullivan, M | 1 |
| Chinol, M; Doherty, PW; Gionet, M; Griffin, T; Hnatowich, DJ; Hunter, R; Kase, KR; Siebecker, DA | 1 |
1 review(s) available for yttrium radioisotopes and Ovarian Neoplasms
| Article | Year |
|---|---|
[Intracavitary administration of liquid radioisotopes].
Topics: Abdominal Neoplasms; Female; Gold Colloid, Radioactive; Humans; Injections, Intraperitoneal; Intestinal Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Radiotherapy; Stomach Neoplasms; Yttrium Radioisotopes | 1978 |
10 trial(s) available for yttrium radioisotopes and Ovarian Neoplasms
| Article | Year |
|---|---|
Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Disease-Free Survival; Female; Humans; Immunoglobulin G; Immunotoxins; Middle Aged; Mucin-1; Neoplasm Staging; Ovarian Neoplasms; Yttrium Radioisotopes | 2008 |
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Heterophile; Antibodies, Monoclonal; Antibodies, Neoplasm; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Immunoconjugates; Injections, Intraperitoneal; Maximum Tolerated Dose; Mice; Middle Aged; Ovarian Neoplasms; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Laparoscopy; Middle Aged; Ovarian Neoplasms; Proportional Hazards Models; Remission Induction; Second-Look Surgery; Treatment Failure; Yttrium Radioisotopes | 2006 |
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epithelial Cells; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Laparoscopy; Mice; Middle Aged; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Secondary Prevention; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer.
Topics: Antibodies, Monoclonal; Female; Humans; Injections, Intraperitoneal; Neoplasm Staging; Ovarian Neoplasms; Radiography; Radioimmunotherapy; Time Factors; Treatment Failure; Yttrium Radioisotopes | 2007 |
Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
Topics: Antibodies; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin G; Immunoglobulin M; Ovarian Neoplasms; Pentetic Acid; Radioimmunotherapy; Yttrium Radioisotopes | 1995 |
Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Brachytherapy; Female; Humans; Mice; Middle Aged; Mucins; Ovarian Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 1994 |
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
Topics: Actuarial Analysis; Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Radioimmunotherapy; Survival Analysis; Time Factors; Yttrium Radioisotopes | 1993 |
Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibody Formation; Breast; Breast Neoplasms; Chelating Agents; Drug Evaluation; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Middle Aged; Neoplasm Staging; Neoplasms; Ovarian Neoplasms; Radioimmunotherapy; Radionuclide Imaging; Stomach Neoplasms; Testicular Neoplasms; Yttrium Radioisotopes | 1992 |
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Bone Marrow; Female; Humans; Immunotoxins; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Radiotherapy Dosage; Remission Induction; Yttrium Radioisotopes | 1990 |
23 other study(ies) available for yttrium radioisotopes and Ovarian Neoplasms
| Article | Year |
|---|---|
PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; Female; Humans; Immunoconjugates; Isothiocyanates; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Pentetic Acid; Positron-Emission Tomography; Radioimmunoassay; Radiopharmaceuticals; Tissue Distribution; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Yttrium Radioisotopes | 2011 |
Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Topics: Adult; Aged; Animals; Antibodies, Neoplasm; Disease-Free Survival; Female; Humans; Immunotoxins; Infusions, Parenteral; Lutetium; Mice; Middle Aged; Ovarian Neoplasms; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2012 |
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Topics: Animals; Female; Humans; Indium Radioisotopes; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Substrate Specificity; Technetium; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2002 |
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Humans; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Transplantation; Organ Specificity; Ovarian Neoplasms; Radiometry; Radiopharmaceuticals; Subtraction Technique; Tissue Distribution; Tomography, Emission-Computed; Trastuzumab; Whole-Body Counting; Yttrium Radioisotopes | 2003 |
An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
Topics: Antineoplastic Agents; Carboplatin; Cell Division; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Resistance, Neoplasm; Drug Synergism; Female; Genetic Therapy; Humans; In Vitro Techniques; Mutation; Ovarian Neoplasms; Paclitaxel; Radioimmunotherapy; Tetrazolium Salts; Thiazoles; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Yttrium Radioisotopes | 2004 |
Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
Topics: Adult; Aged; Antibodies, Monoclonal; Biotin; Female; Humans; Immunotoxins; Middle Aged; Ovarian Neoplasms; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Yttrium Radioisotopes | 2004 |
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Immunoglobulin Variable Region; Immunotoxins; Isothiocyanates; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Pentetic Acid; Radioimmunotherapy; Radionuclide Imaging; Receptor, ErbB-2; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation.
Topics: Animals; Dose Fractionation, Radiation; Female; Humans; Indium Radioisotopes; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
Topics: Antibodies, Monoclonal; Carcinoma; Female; Humans; Isotope Labeling; Organometallic Compounds; Ovarian Neoplasms; Radioimmunotherapy; Tissue Distribution; Yttrium Radioisotopes | 2005 |
Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; CA-125 Antigen; Female; Humans; Immunoglobulin G; Iodine Radioisotopes; Mice; Ovarian Neoplasms; Radioimmunotherapy; Tissue Distribution; Transplantation, Heterologous; Yttrium Radioisotopes | 2005 |
Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; CA-125 Antigen; Carcinoma; Female; Humans; Immunoconjugates; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radioimmunotherapy; Transplantation, Heterologous; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2006 |
Consolidation for ovarian cancer in remission.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Chemotherapy, Adjuvant; Female; Humans; Membrane Proteins; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2006 |
alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Integrin alphaVbeta3; Isotope Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Protein Conformation; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2008 |
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.
Topics: Alpha Particles; Animals; Ascites; Astatine; Colloids; Dysprosium; Electrons; Female; Half-Life; Intestinal Mucosa; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Ovarian Neoplasms; Particle Size; Phosphorus Radioisotopes; Radioisotopes; Thyroid Gland; Yttrium Radioisotopes | 1984 |
Correlation of beta-camera imaging and immunohistochemistry in radioimmunotherapy using 90Y-labeled monoclonal antibodies in ovarian cancer animal models.
Topics: Animals; Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoembryonic Antigen; Disease Models, Animal; Female; Fibrin; Immunohistochemistry; Keratins; Mice; Mice, Nude; Ovarian Neoplasms; Proteins; Radioimmunotherapy; Radionuclide Imaging; Statistics as Topic; Yttrium Radioisotopes | 1994 |
Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Female; Fibrin; Humans; Immunohistochemistry; Injections, Intralesional; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Radioimmunotherapy; Survival Analysis; Tissue Distribution; Yttrium Radioisotopes | 1993 |
Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Topics: Animals; Female; Humans; Immunoconjugates; Immunoglobulin M; Indium Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Peritoneal Neoplasms; Radioimmunotherapy; Tissue Distribution; Yttrium Radioisotopes | 1998 |
Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.
Topics: Animals; Antibodies, Monoclonal; Dose Fractionation, Radiation; Female; Humans; Immunoglobulin M; Mice; Mice, Nude; Ovarian Neoplasms; Peritoneal Neoplasms; Radioimmunotherapy; Survival; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Yttrium Radioisotopes | 2000 |
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Injections, Intraperitoneal; Interferons; Middle Aged; Ovarian Neoplasms; Radioimmunotherapy; Tissue Distribution; Yttrium Radioisotopes | 1991 |
Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions.
Topics: Antibodies, Monoclonal; Bone Marrow; Evaluation Studies as Topic; Female; Humans; Injections, Intraperitoneal; Ovarian Neoplasms; Yttrium Radioisotopes | 1990 |
Intraperitoneal radioimmunotherapy for ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Bone Marrow; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intraperitoneal; Iodine Radioisotopes; Middle Aged; Ovarian Neoplasms; Prognosis; Yttrium Radioisotopes | 1989 |
Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Topics: Antibodies, Monoclonal; Bone Marrow; Female; Half-Life; Humans; Iodine Radioisotopes; Ovarian Neoplasms; Peritoneum; Radiotherapy Dosage; Yttrium Radioisotopes | 1988 |
Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody.
Topics: Animals; Antibodies, Monoclonal; Female; Humans; Immunization; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Ovary; Pentetic Acid; Radiation Dosage; Radionuclide Imaging; Reoperation; Tissue Distribution; Yttrium Radioisotopes | 1988 |